Funding for this research was provided by:
Received: 28 May 2020
Accepted: 30 May 2020
First Online: 26 June 2020
Ethics approval and consent to participate
: The National Ethics Committee of the Greek Drug Administration has approved the study. The file number/reference number of the ethical approval judgement is 45309/2020, date of approval 21 May 2020). Link to the public listing of the ethical approval, 41/20: ExternalRef removedWe certify that this trial has received ethical approval from the appropriate ethical committee.All patients participating in the study or their legal representative will provide signed informed consent.
: Not applicable
: The following pending patents are relevant to the work in this manuscript• PCT/EP2019/087056. L-triiodothyronine (T3) for use in limiting microvascular obstruction• Greek Patent Office, number of case: 22-0002577373. Composition comprising L-triiodothyronine (T3) for use in the treatment of critically ill patients with coronavirus infection.IT, managing director of Uni-Pharma, is the sponsor and owner of these patents. CP and IM are the inventors and hold royalties in relation to these patents.The authors GK, AA and AT declare that they have no competing interests.